Kidney disease drug faces Long-Term safety test
NCT ID NCT06858319
Summary
This study follows patients who previously participated in zigakibart trials to monitor long-term safety and effectiveness for IgA nephropathy, a chronic kidney disease. About 220 adults will receive the drug every two weeks for up to two years while researchers track side effects and kidney function. The goal is to determine if this treatment remains safe and beneficial for extended use in controlling this progressive condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Colorado Kidney Care Nephrology
RECRUITINGDenver, Colorado, 80230, United States
Contact
-
Knoxville Kidney Center Pllc
RECRUITINGBrentwood, Tennessee, 37027-4528, United States
Contact
-
NY Nephrology
RECRUITINGClifton Park, New York, 12065, United States
Contact Phone: •••-•••-••••
Contact
-
Novartis Investigative Site
RECRUITINGBuenos Aires, Buenos Aires F.D., 1280, Argentina
-
Novartis Investigative Site
RECRUITINGSanta Fe, S3000EPV, Argentina
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 03080, South Korea
Conditions
Explore the condition pages connected to this study.